Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide versus placebo in transfusion-dependent lower-risk myelodysplastic syndromes without del(5q)
2009-011513-24Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Lenalidomide with Placebo (2 arms). Started Oct 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2009-011513-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011513-24.